Cargando…

A case of a patient receiving combination therapy with paclitaxel plus bevacizumab and adoptive activated αβ T‐cell immunotherapy in advanced breast cancer

Detalles Bibliográficos
Autores principales:	Masuda, Takaaki, Nonami, Atsushi, Tanaka, Fumiaki, Ando, Yuki, Eto, Masatoshi, Mimori, Koshi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2020
Materias:	Commentaries
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7839766/ https://www.ncbi.nlm.nih.gov/pubmed/33277749 http://dx.doi.org/10.1111/tbj.14108

Ejemplares similares

Artificial intelligence-assisted drug repurposing via “chemical-induced gene expression ranking”
por: Masuda, Takaaki, et al.
Publicado: (2022)

Successful Treatment with Hepatic Arterial Infusion Chemotherapy in a Breast Cancer Patient with Multiple Liver Metastases Who Declined Systemic Therapy
por: Masuda, Takaaki, et al.
Publicado: (2021)

Comparison of neoadjuvant nab‐paclitaxel plus immunotherapy versus paclitaxel plus immunotherapy for esophageal squamous cell carcinoma
por: Yang, Yafan, et al.
Publicado: (2023)

A Case of Biphasic Pulmonary Blastoma Treated with Carboplatin and Paclitaxel plus Bevacizumab
por: Sakata, Shinya, et al.
Publicado: (2015)

The efficacy and safety of paclitaxel plus bevacizumab therapy in breast cancer patients with visceral crisis
por: Funasaka, Chikako, et al.
Publicado: (2021)

Risk Factors for Early Onset of Proteinuria in Patients Receiving Atezolizumab Plus Bevacizumab for Unresectable Hepatocellular Carcinoma
por: Ando, Yuwa, et al.
Publicado: (2022)

Atezolizumab plus bevacizumab and tremelimumab plus durvalumab: how should we choose these two immunotherapy regimens for advanced hepatocellular carcinoma?
por: Hatanaka, Takeshi, et al.
Publicado: (2022)

The prediction of early progressive disease in patients with hepatocellular carcinoma receiving atezolizumab plus bevacizumab
por: Takeuchi, Yasuto, et al.
Publicado: (2023)

Impact of body mass index in patients receiving atezolizumab plus bevacizumab for hepatocellular carcinoma
por: Vithayathil, Mathew, et al.
Publicado: (2023)

Systematic Review and Network Meta-Analysis of Bevacizumab Plus First-Line Topotecan-Paclitaxel or Cisplatin-Paclitaxel Versus Non–Bevacizumab-Containing Therapies in Persistent, Recurrent, or Metastatic Cervical Cancer
por: Rosen, Virginia M., et al.
Publicado: (2017)

Comparison of Neoadjuvant Chemotherapy Efficiency in Advanced Ovarian Cancer Patients Treated With Paclitaxel Plus Carboplatin and Intraperitoneal Bevacizumab vs. Paclitaxel With Carboplatin
por: Tao, Yin, et al.
Publicado: (2022)

Prognostic and predictive factors for angiosarcoma patients receiving paclitaxel once weekly plus or minus bevacizumab: an ancillary study derived from a randomized clinical trial
por: Lebellec, Loïc, et al.
Publicado: (2018)

Bevacizumab Exacerbates Paclitaxel-Induced Neuropathy: A Retrospective Cohort Study
por: Matsuoka, Ayumu, et al.
Publicado: (2016)

Real-world efficacy and safety of bevacizumab single-maintenance therapy following platinum-paclitaxel chemotherapy plus bevacizumab in patients with advanced cervical cancer
por: Kotaka, Saki, et al.
Publicado: (2023)

Cisplatin plus paclitaxel and maintenance of bevacizumab on tumour progression, dissemination, and survival of ovarian carcinoma xenograft models
por: Oliva, P, et al.
Publicado: (2012)

Baseline neutrophil-to-lymphocyte ratio and c-reactive protein predict efficacy of treatment with bevacizumab plus paclitaxel for locally advanced or metastatic breast cancer
por: Miyagawa, Yoshimasa, et al.
Publicado: (2020)

Bevacizumab-Induced Thrombotic Microangiopathy (TMA) in Metastatic Lung Adenocarcinoma Patients Receiving Nivolumab Combined with Bevacizumab, Carboplatin and Paclitaxel: Two Case Reports
por: Hsu, Ping-Chih, et al.
Publicado: (2023)

MicroRNAs as Biomarkers in Colorectal Cancer
por: Masuda, Takaaki, et al.
Publicado: (2017)

Nasopharyngeal carcinoma treated with bevacizumab combined with paclitaxel liposome plus cisplatin: a case report and literature review
por: He, Wan, et al.
Publicado: (2016)

A Molecular Docking Study Reveals That Short Peptides Induce Conformational Changes in the Structure of Human Tubulin Isotypes αβI, αβII, αβIII and αβIV
por: Ebenezer, Oluwakemi, et al.
Publicado: (2023)

Drug repositioning in cancer: The current situation in Japan
por: Masuda, Takaaki, et al.
Publicado: (2020)

Immunotherapy in hepatocellular carcinoma: evaluation and management of adverse events associated with atezolizumab plus bevacizumab
por: Hsu, Chiun, et al.
Publicado: (2021)

Advanced hepatocellular carcinoma with response to lenvatinib after atezolizumab plus bevacizumab
por: Yano, Shigeki, et al.
Publicado: (2021)

Cost-effectiveness of bevacizumab plus paclitaxel versus paclitaxel for the first-line treatment of HER2-negative metastatic breast cancer in specialist oncology centers in France
por: Petitjean, Audrey, et al.
Publicado: (2019)

Changing the Treatment Paradigm for Hepatocellular Carcinoma Using Atezolizumab plus Bevacizumab Combination Therapy
por: Kudo, Masatoshi
Publicado: (2021)

Paclitaxel-resistant advanced recurrent breast cancer: a case of partial response due to addition of bevacizumab to paclitaxel therapy: a case report
por: Ishizuna, Kazuo, et al.
Publicado: (2013)

Predictive biomarkers of survival in patients with advanced hepatocellular carcinoma receiving atezolizumab plus bevacizumab treatment
por: Chon, Young Eun, et al.
Publicado: (2022)

CD103+ intraepithelial T cells in high-grade serous ovarian cancer are phenotypically diverse TCRαβ+ CD8αβ+ T cells that can be targeted for cancer immunotherapy
por: Komdeur, Fenne L., et al.
Publicado: (2016)

Erratum to “Immunotherapy in hepatocellular carcinoma: evaluation and management of adverse events associated with atezolizumab plus bevacizumab”
Publicado: (2021)

Neuroendocrine Carcinoma of the Stomach: A Response to Combination Chemotherapy Consisting of Ramucirumab Plus Paclitaxel
por: Matsubara, Yuki, et al.
Publicado: (2017)

Maintenance bevacizumab beyond first-line paclitaxel plus bevacizumab in patients with Her2-negative hormone receptor-positive metastatic breast cancer: efficacy in combination with hormonal therapy
por: Fabi, Alessandra, et al.
Publicado: (2012)

Cisplatin plus paclitaxel chemotherapy with or without bevacizumab in postmenopausal women with previously untreated advanced cervical cancer: a retrospective study
por: Chu, Guanghua, et al.
Publicado: (2021)

Genesis of the αβ T-cell receptor
por: Dupic, Thomas, et al.
Publicado: (2019)

Effect of neutropenia on survival outcomes of patients with metastatic colorectal cancer receiving trifluridine/tipiracil plus bevacizumab
por: Kamiimabeppu, Daisaku, et al.
Publicado: (2021)

Rapid Generation of TCR and CD8αβ Transgenic Virus Specific T Cells for Immunotherapy of Leukemia
por: Bajwa, Gagan, et al.
Publicado: (2022)

Preservation of Antigen-Specific Functions of αβ T Cells and B Cells Removed from Hematopoietic Stem Cell Transplants Suggests Their Use As an Alternative Cell Source for Advanced Manipulation and Adoptive Immunotherapy
por: Li Pira, Giuseppina, et al.
Publicado: (2017)

Bevacizumab‐associated intestinal perforation and perioperative complications in patients receiving bevacizumab
por: Yoshimoto, Toshiaki, et al.
Publicado: (2020)

Low‐dose gemcitabine plus nab‐paclitaxel versus standard‐dose gemcitabine plus nab‐paclitaxel in elderly patients with metastatic pancreatic cancer: A randomized Phase II trial
por: Kamata, Ken, et al.
Publicado: (2023)

Generation and application of human induced‐stem cell memory T cells for adoptive immunotherapy
por: Kondo, Taisuke, et al.
Publicado: (2018)

Regorafenib is suitable for advanced colorectal cancer patients who have previously received trifluridine/tipiracil plus bevacizumab
por: Matsumoto, Toshihiko, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_7o3768r5sefvujdrjgo0h5ho2e